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Abstract
Introduction: We functionally analyzed a frameshift mutation in the SCN5A gene encoding cardiac Na+ channels
(Nav1.5) found in a proband with repeated episodes of ventricular fibrillation who presented bradycardia and
paroxysmal atrial fibrillation. Seven relatives also carry the mutation and showed a Brugada syndrome with an
incomplete and variable expression. The mutation (p.D1816VfsX7) resulted in a severe truncation (201 residues) of
the Nav1.5 C-terminus.
Methods and Results: Wild-type (WT) and mutated Nav1.5 channels together with hNavβ1 were expressed in CHO
cells and currents were recorded at room temperature using the whole-cell patch-clamp. Expression of
p.D1816VfsX7 alone resulted in a marked reduction (≈90%) in peak Na+ current density compared with WT channels.
Peak current density generated by p.D1816VfsX7+WT was ≈50% of that generated by WT channels. p.D1816VfsX7
positively shifted activation and inactivation curves, leading to a significant reduction of the window current. The
mutation accelerated current activation and reactivation kinetics and increased the fraction of channels developing
slow inactivation with prolonged depolarizations. However, late INa was not modified by the mutation. p.D1816VfsX7
produced a marked reduction of channel trafficking toward the membrane that was not restored by decreasing
incubation temperature during cell culture or by incubation with 300 μM mexiletine and 5 mM 4-phenylbutirate.
Conclusion: Despite a severe truncation of the C-terminus, the resulting mutated channels generate currents, albeit
with reduced amplitude and altered biophysical properties, confirming the key role of the C-terminal domain in the
expression and function of the cardiac Na+ channel.
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Introduction
SCN5A gene encodes the α-subunit of cardiac voltage-gated
Na+ channels (Nav1.5), which generate the inward sodium
current (INa) that is critical for the genesis and propagation of
action potentials and, in turn, determines cardiac excitability
and conduction velocity of the electrical impulse within the
heart [1,2]. Nav1.5 comprises 4 homologous domains, DI to
PLOS ONE | www.plosone.org 1 November 2013 | Volume 8 | Issue 11 | e81493
DIV, each of which contains 6 transmembrane helices (S1 to
S6) with intracellular N- and C-terminal domains [3]. Mutations
in SCN5A have been associated with several arrhythmogenic
diseases. Gain-of-function mutations leading to an increased
late INa (INa,L) cause long QT syndrome type 3 (LQT3), whereas
loss-of-function mutations resulting in a decreased peak INa
may cause a variety of arrhythmogenic syndromes such as
Brugada syndrome [characterized by the elevation of the ST
segment in the right precordial leads of the ECG (BrS)],
progressive cardiac conduction disease, sick sinus syndrome,
atrial fibrillation (AF) [4], and sudden infant death syndrome
[2-4]. Furthermore, loss-of-function Nav1.5 mutations have
been described in patients with idiopathic ventricular fibrillation
(IVF), an uncommon and lethal condition which presents itself
as syncope or sudden cardiac death in young people with
normal hearts and without electrophysiological manifestations
of inherited arrhythmogenic syndromes [5-7]. Therefore,
Nav1.5 mutations can render a broad spectrum of inherited
cardiac arrhythmias. Furthermore, some SCN5A mutations can
lead to complex diseases associating different phenotypic traits
such as, for instance, bradycardia, conduction disease, LQT3,
and BrS, i.e., the so-called overlap syndromes [8].
C-terminus of Nav1.5 channels which comprises 243
residues plays an important role in regulating both channel
gating and membrane expression. The predicted structure of
the first half of the C-terminal domain consists of six helices
(H1-H6) while the second half is not structured. It has been
proposed that C-terminus helices participate in the control of
inactivation through stabilization of the closed gate [9,10].
Furthermore, C-terminal domain bears several regions critical
for protein-protein interaction, particularly the PDZ binding
domain, which, in turn, are critical for channel trafficking and
surface expression. A huge amount of disease-causing
mutations have been identified in transmembrane segments of
Nav1.5. However, mutations in the C-terminal domain are less
frequent and only a few of them have been studied functionally
[1-3,11-13].
Here we report a novel heterozygous frameshift mutation in
SCN5A that results in a severe truncation of the C-terminal
domain found in a proband with repeated episodes of
ventricular fibrillation who presented bradycardia and
paroxysmal AF. Heterologous expression of the mutation
resulted in a marked decrease of peak INa density mainly
caused by a reduced channel trafficking toward the plasma
membrane and in severe alterations in channel activation and
inactivation. Interestingly, unlike other C-terminal domain
truncating mutations [11], the mutation here presented did not
modify INa,L suggesting that deletions of different lengths can
differentially affect gating properties of the variants. This fact is
important since these differences contribute to determining the
phenotype of the carriers. Furthermore, our results suggest that
this SCN5A mutation can result in multiple rhythm disturbances
within the same family, presenting with extensive variability in




The study was approved by the Investigation Committee of
the Hospital Universitario Virgen de las Nieves and conforms to
the principles outlined in the Declaration of Helsinki. Written
informed consent was obtained for the genetic screening test of
the proband and all the relatives studied. Genomic DNA was
isolated from white blood cells by conventional methods
[14,15]. The whole codifying sequence and the flanking intronic
regions of KCNQ1, KCNH2, KCNJ2, SCN5A, KCNE1, and
KCNE2 genes were amplified by polymerase chain reaction
and directly sequenced. SCN5A (hH1 clone) mutation was
introduced using the QuikChange Site-Directed Mutagenesis
kit (Stratagene, USA) and confirmed by direct DNA sequencing
[15].
Electrophysiological analysis
Wild-type (WT) and mutated Nav1.5 channels (0.8 µg)
together with the ancillary subunit hNavβ1 (0.8 µg) were
transiently transfected in CHO cells by using Fugene 6 (Roche
Diagnostics, Switzerland). Currents were recorded at room
temperature using the whole-cell patch-clamp configuration
following previously described methods [15]. Recording
pipettes were pulled from 1.0 mm o.d. borosilicate capillary
tubes (GD1, Narishige Co., Ltd, Japan) using a programmable
patch micropipette puller (Model P-2000 Brown-Flaming, Sutter
Instruments Co., USA) and were heat-polished with a
microforge (Model MF-830, Narishige). Micropipette resistance
ranged from 0.5 to 1.5 MΩ when filled with the internal solution
and immersed in the external solution. In all experiments,
series resistance was compensated manually by using the
series resistance compensation unit of the Axopatch-200B
amplifier, and usually ≥80% compensation was achieved.
Mean peak maximum Nav1.5 current (INav1.5) amplitude,
uncompensated access resistance, and capacitance averaged
3.0±0.4 nA, 1.6±0.2 MΩ, and 7.8±0.7 pF (n=69), respectively.
Thus, under our experimental conditions no significant voltage
errors (<5 mV) due to series resistance were expected with the
micropipettes used. Currents were filtered at half the sampling
frequency and stored on the hard disk of a computer for
subsequent analysis by using p.CLAMP9 software (Molecular
Devices, USA). When WT and mutant Nav1.5 channels were
coexpressed, a 0.5:0.5 ratio was used. To minimize the
influence of the expression variability of transiently transfected
mammalian cell lines, each construct was tested in a large
number of cells obtained from at least three different
transfection batches. Cells were perfused with an external
solution containing (mM): NaCl 136, KCl 4, CaCl2 1.8, MgCl2 1,
HEPES 10, and glucose 10 (pH 7.4 with NaOH). The internal
solution contained (mM): NaF 10, CsF 110, CsCl 20, HEPES
10, and EGTA 10 (pH 7.35 with CsOH). In a separate group of
experiments, INav1.5 currents generated by WT and mutant
channels were recorded in the absence of F- as previously
described by Ruan et al [16]. In this group of experiments the
composition of the external solution was (mM): NaCl 130,
CaCl2 2, CsCl 5, MgCl2 1.2, HEPES 10, and glucose 5 (pH=7.4
with CsOH), while that of the internal solution was (mM):
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aspartic acid 50, CsCl 60, Na2-ATP 5, EGTA 11, HEPES 10,
CaCl2 1, and MgCl2 1 (pH=7.4 with CsOH).
The protocol to obtain INav1.5-voltage (I-V) curves consisted of
50 ms pulses in 5 mV increments from –120 mV to potentials
between −80 and +50 mV. To minimize the contribution of
time-dependent shifts of channel availability, all data were
collected 20 min after establishing the whole-cell configuration.
Activation curves were constructed plotting the normalized
peak conductance as a function of the membrane potential.
The conductance was estimated by the equation [G=I/(Vm-
Erev)], where G is the conductance at the test potential Vm, I
represents the peak maximum current at Vm, and Erev is the
reversal potential. To determine the Erev, the current density-
voltage relationships were fitted to a function of the form [I=(Vm-
Erev)*Gmax*(1+exp[Vm-Vh]/k)-1], where I is the peak current
elicited at the test potential Vm, Gmax is the maximum
conductance, and k is the slope factor. To obtain the
inactivation curves, a two-step protocol was used. The first
500-ms conditioning pulse from –120 mV to potentials between
–140 and –20 mV was followed by a 20-ms test pulse to –20
mV. Inactivation curves were constructed by plotting the
current amplitude obtained with the test pulse normalized to the
largest peak current, as a function of the voltage command of
the conditioning pulse. The fit of a Boltzmann function to the
data yielded the midpoint (Vh) and the slope (k) of the activation
and inactivation curves. We also analyzed the effect of the
mutation on the Nav1.5 window current. The overlap of steady-
state activation and steady-state inactivation curves of Na+
channels identifies a range of voltages (i.e., window) where the
channels have a small probability of being partially but not fully
inactivated [17]. The probability of being within this window was
calculated from the product of activation and steady-state
inactivation parameters through the following equation:
Probability = (1/{1 + exp[(Vhact − V)/kact]} × ((1 − C)/{1 + exp[(V −
Vhinact)/kinact]} + C) as previously described [18].
Membrane trafficking
To identify trafficking defects induced by the mutation, Na+
channels (hH1 clone) conjugated to green fluorescent protein
(GFP) were localized by confocal microscopy [19]. In this
construct, GFP was inserted to the C-terminal domain of the
Nav1.5 channel as previously described [20]. CHO cells were
transfected with the constructs and collected 48 h after
transfection following the procedures described above. In a
group of experiments, density, and voltage-dependence of
activation and inactivation of the currents generated by Nav1.5
WT channels conjugated or not with GFP were compared.
Currents were recorded as described above. For confocal
microscopy experiments, cells were seeded on fibronectine-
coated coverslips and allowed to attach for 30 min. Afterwards,
they were washed with phosphate buffered saline (PBS) and
fixed with 4% paraformaldehyde for 10 min. Then, they were
washed again and incubated for 10 min with a wheat germ
agglutinin Alexa Fluor 647 conjugate (Invitrogen, UK), a
fluorescent plasma membrane dye. Finally, the coverslips were
washed three times with PBS and mounted using the Prolong
(Invitrogen) antifading mounting medium. Confocal microscopy
was performed with a Leica TCS-SP5 AOBS confocal
microscope (Mannheim, Germany) with 20x and 63x oil
immersion optics. Laser lines at 488 nm and 633 nm for
excitation of GFP and Alexa Fluor were provided by an Argon
laser and a Helio-Neon laser, respectively. Detection ranges
were set to eliminate crosstalk between fluorophores. The XY
frame was set to 512×512 pixels, and laser intensity was set to
6% power. The z axis was changed in ≈0.50 μm increments by
computer control through the entire volume of the cell.
Colocalization of channels and membrane marker was
quantified using BioImageXD software for calculation of the
percentage of colocalized voxels.
Statistical analysis
Results are expressed as mean±SEM. Unpaired t-test or
one-way ANOVA followed by Newman-Keuls test were used to
assess statistical significance where appropriate. A value of
P<0.05 was considered significant.
Results
Case description and genetic analysis
The proband, a 53-year old woman with no family history of
cardiac disease or sudden death, was asymptomatic until she
was admitted to the hospital after a syncopal episode.
Electrocardiographic monitoring showed the presence of
polymorphic ventricular tachycardia with spontaneous
cessation and frequent monomorphic premature ventricular
complexes with left bundle branch block and left superior axis
morphology and short coupling intervals, which triggered
repeated episodes of ventricular fibrillation (Figure 1A). These
episodes were resistant to treatment with β-blockers,
amiodarone, procainamide, and isoproterenol, requiring 20
defibrillations over a period of 72 h [21]. Afterwards, an internal
cardioverter defibrillator was implanted and since then she has
been under regular follow up with no more subsequent
arrhythmic events up to now.
Interestingly, the proband presented sinus bradycardia
(45-50 bpm) on basal status and under flecainide (Figure 1B)
and also paroxysmal AF. Structural heart disease and other
possible cardiac conditions were excluded by
echocardiograghy, cardiac magnetic resonance imaging, and
coronary arteriography. Drug challenge with flecainide (Figure
1B) and epinephrine QT stress test were negative.
Proband`s genetic analysis identified a frameshift mutation
consisting in a T insertion at position 98747 of SCN5A (exon
28) (Figure 2C) resulting in the substitution of the aspartic acid
at position 1816 by a valine followed by 6 miscoded residues
prior to a termination codon (p.D1816VfsX7) (Figure 2A and
2B). Thus, the mutation leads to the deletion of C-terminal 201
aminoacids of Nav1.5 protein. As shown in Figure 2B, this
region which includes the D1816 residue, is highly conserved
among human Nav1.x clones and Nav1.5 channels of different
species. Importantly, the mutation was not observed in more
than 200 control subjects. Moreover, sequence analysis of all
other exons of SCN5A did not reveal any other mutation and
screening for mutations in the other genes tested was also
negative. D1816VfsX7 mutation has not been described either
Frameshift Mutation in the C-Terminus of SCN5A
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in the 1000 Genomes project or in the NHLBI Exome
Sequencing Project.
Genetic screening of fifteen family members revealed that
seven of them also carried the mutation (Figure 1C).
Electrocardiogram (ECG) recording, echocardiogram and
Figure 1.  Clinical characterization and pedigree of the proband.  A. ECG of the proband at hospital admission with an episode
of ventricular fibrillation initiated by a premature ventricular contraction (paper speed 25 mm/s). Reprinted from [21] under a CC BY
license, with permission from Elsevier original copyright (2011). B. 12-Lead ECG of the proband after flecainide continuous infusion
at 2 mg/kg for 10 min (paper speed 25 mm/s). C. Pedigree of the affected family. Circles and squares represent female and male
subjects, respectively. White and black symbols represent unaffected and affected individuals, respectively. The arrow denotes the
proband. Diagonal lines indicate deceased subjects. The asterisk denotes proband`s relatives subjected to genetic and
electrophysiological analyses (including flecainide test). Patient named in the figure as III.4 was excluded from the pharmacological
test and ECG analysis because she had suffered Tetrallogy of Fallot that had been corrected in childhood, although she is a
mutation carrier. δ denotes proband`s relatives who displayed type 1 BrS pattern after flecainide challenge. D. ECG of the proband´s
son (top) and sister (bottom) after flecainide challenge.
doi: 10.1371/journal.pone.0081493.g001
Table 1. Comparison of ECG features between p.D1816VfsX7 mutation carriers and non carriers.
ECG parameters p.D1816VfsX7 non carriers p.D1816VfsX7 carriers
N 8 8
Spontaneous Brugada pattern 0 0
PR interval (ms) 150±29 197±27*
QRS interval (ms) 91±12 113±16*
QTc interval (ms) 392.3±9.0 398.7±6.1
Atrial fibrillation (%) 0 (0%) 2 (25%)
Values are the mean±SEM of 8 non carriers and 8 carriers in each case. * P<0.05 vs non carriers.
doi: 10.1371/journal.pone.0081493.t001
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flecainide tests were also performed on all the relatives
studied. As can be observed in Table 1, PR and QRS intervals,
but not QTc intervals, were significantly prolonged in the
mutation carriers compared with non-carriers. Interestingly, the
family screening detected an abnormal basal ECG in a son (24
years old; III:1) and a sister (59 years old; II:4) of the proband
carrying the SCN5A mutation, with slightly widened QRS in V1-
V3 and positive response with development of type 1 BrS
pattern after flecainide continuous infusion at 2 mg/kg for 10
min (Figure 1D and Table 2). Another proband’s sister
exhibited permanent AF (II:8). Moreover, another relative
carrying the mutation (III:6) has presented a syncopal episode
in the past (Table 2). The remaining relatives were all
asymptomatic at the present time.
Functional characterization
Figure 3A shows INav1.5 traces recorded by applying 50 ms
pulses from -120 mV to potentials between -80 and +50 mV in
cells expressing WT and p.D1816VfsX7 channels. Recent
experimental evidence points to the existence of some kind of
Figure 2.  p.D1816VfsX7 mutation characteristics and localization.  A. Topological diagram of Nav1.5 showing the location of
D1816 residue. H1 to H6: each of the six α-helices present in the proximal half of the C-terminus. IQ: IQ motif which constitutes a
calmodulin binding site. PY: PY motif which constitutes a binding site for E3 ubiquitin-protein ligases. PDZ: PDZ motif which
constitutes a binding site for SAP97, PTPH1, and syntrophins. B. Sequence alignments of a segment of the C-terminus of SCN5A
homologs in 7 different species and SCNXA family sodium channel expressed in human tissues. The sequence of p.D1816VfsX7
mutation is also shown. The respective accession numbers are NP_001159435.1, NP_001035232.1, NP_001075145.1,
NP_000325.4, NP_000326.2, NP_002967.2, NP_001171455.1, and NP_002968.1 for SCN1-5/7-9, and for the different species are:
XP_001171891.2 (Pan troglodytes), NP_001240789.1 (Mus musculus), NP_001153634.1 (Rattus norvegicus), NP_776883.1 (Bos
taurus), NP_001157367.1 (Equus caballus), and XP_001232818.2 (Gallus gallus). “*” means that the residues in that column are
identical in all the sequences in the alignment. “:”indicates conservation between groups of strongly similar properties. “.”indicates
conservation between groups of weakly similar properties. C. DNA sequence chromatograms of the proband depicting the
heterozigous insertion in exon 28 of SCN5A.
doi: 10.1371/journal.pone.0081493.g002
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interaction between Nav1.5 subunits to form functional
channels, in such a way that some trafficking deficient
mutations produced dominant negative effects on WT channels
[15,22]. Therefore, to mimic the heterozygous state of the
patient and to determine whether the p.D1816VfsX7 mutation
produced a dominant negative effect on WT channels, WT and
p.D1816VfsX7 channels were cotransfected using a 0.5:0.5
ratio (p.D1816VfsX7+WT). Cells were always cotransfected
with the gene encoding hNavβ1 subunit (1:1 ratio). Peak
current density generated by p.D1816VfsX7 (-69.8±24.7 pA/pF)
was dramatically smaller than that generated by WT channels
(-691±105 pA/pF) (n>12; P<0.01) (Figures 3A-C). Peak current
density generated by p.D1816VfsX7+WT channels (-350±119
pA/pF) was approximately 50% of the WT value (Figures 3A-
C), a result which is consistent with haploinsuficiency without
producing dominant negative effects. Interestingly,
p.D1816VfsX7 peak current occurred at more positive
potentials than that of WT channels (Figure 3B), suggesting
that the mutation altered voltage dependence of activation.
Indeed, as can be observed in Figure 4A and Table 3,
p.D1816VfsX7 shifted ~18 mV positively the activation curve
obtained by plotting the normalized peak conductance as a
function of the membrane potential. Co-expression of WT with
p.D1816VfsX7 mutation partially reversed this gating defect
produced by the mutation (Figure 4A and Table 3). The effects
of the mutation on the activation kinetics were assessed by
measuring the time to peak. Interestingly, p.D1816VfsX7
significantly accelerated the time course of current activation,
an effect that was completely abrogated when the mutant
channel was cotransfected with WT (Table 3). Voltage
dependence of steady-state inactivation was tested by applying
500 ms conditioning pulses from -120 to potentials between
-140 and -20 mV followed by a test pulse to -20 mV.
p.D1816VfsX7 mutation alone or in combination with WT
channels shifted the midpoint of the inactivation curve to more
positive potentials, without modifying the slope factor curve
(Figure 4B and Table 3). Overall, these results suggested that
p.D1816VfsX7 mutation profoundly affected the voltage
dependence of Nav1.5 channels activation and inactivation. To
rule out that these effects can be secondary to the presence of
F- ion in the intracellular solution, currents generated by WT
and p.D1816VfsX7 channels were recorded in the absence of
this ion. Importantly, the changes produced by the mutation
were quantitatively and qualitatively identical when the currents
were recorded in the absence of F- in the intracellular solution
(Table 4).
We also determined the effects of the mutation on the
window current. The overlap of the activation and steady-state
inactivation of Na+ channels identifies a range of voltages (i.e.,
window) where the channels have a small probability of being
partially but not fully inactivated. The plot of the probability of
being within the window calculated from the product of the
fitted activation and steady-state inactivation parameters
(Figure 5A) demonstrated that p.D1816VfsX7 decreased the
amplitude of the window current and shifted its peak to more
depolarized potentials (from 0.29±0.1% at -60 mV for WT
channels to 0.12±0.04% at -40 mV for p.D1816VfsX7 channels;
P<0.05).
To determine putative modifications on the kinetics of the
fast inactivation process, a biexponential function was fitted to
the decay of the peak current traces elicited by each construct.
Interestingly, both fast and slow time constants of inactivation
of p.D1816VfsX7 were indistinguishable from those of WT
channels (Table 3), demonstrating that the mutation did not
modify fast inactivation kinetics. Furthermore, the mutation did
not modify the current density after 500 ms pulses to -20 mV,
Table 2. Clinical phenotype of afected mutation carriers.
Patient, (gender) Clinical phenotype
Proband, (F) Syncope, Ventricular tachycardia and fibrillation, bradycardia and paroxysmal atrial fibrillation.
II:4 (F) Abnormal basal ECG. Development of type 1 BrS after flecainide test.
II:8 (F) Permanent atrial fibrillation
III:1 (M) Abnormal basal ECG. Development of type 1 BrS after flecainide test.
III:6 (M) Syncope.
BrS: Brugada Syndrome. ECG: Electrocardiogram, F: female, M: male.
doi: 10.1371/journal.pone.0081493.t002
Table 3. Effects of p.D1816VfsX7 mutation on time-, and voltage-dependent Nav1.5 channel properties.
Nav1.5 construct Activation Inactivation Reactivation
 Vh (mV) k (mV) Time to peak (ms) Vh (mV) k (mV) τf (ms) τs (ms) τf (ms) τs (ms)
WT -45.2±1.4 5.6±0.4 0.53±0.03 -82.1±1.9 6.5±0.3 0.9±0.1 5.7±0.3 3.5±0.6 18.8±2.4
p.D1816VfsX7 -27.3±2.1* 5.4±0.4 0.28±0.02* -61.5±2.5* 6.0±1.0 0.8±0.1 4.7±0.6 1.5±0.3* 24.5±3.4
p.D1816VfsX7+WT -38.5±6.6* # 5.5±0.5 0.54±0.06 -69.6±6.5* # 6.1±0.4 1.1±0.1 5.8±1.0 2.2±0.4* # 17.9±4.0
Vh and k: midpoint and slope values of the activation and inactivation curves. τf and τs: fast and slow time constants of inactivation or reactivation
Values are mean±SEM of >10 experiments. * P<0.01 vs WT. # P<0.01 vs p.D1816VfsX7
doi: 10.1371/journal.pone.0081493.t003
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indicating that the density of the INaL was not changed by the
mutation (Figure 5B).
Recovery from fast inactivation was analyzed by applying
two test pulses to -20 mV with increasing coupling intervals
(Figure 6A). The holding and the potential between pulses
were -120 mV. Recovery time course was depicted by
biexponential functions yielding the fast and slow time
constants reported in Table 3. Interestingly, recovery from fast
inactivation of p.D1816VfsX7 channels was significantly faster
than those of WT and p.D1816VfsX7+WT channels (Figure 6A
Table 4. Comparison of voltage-dependence of activation and inactivation parameters from the currents generated by WT
and mutant Nav1.5 recorded in the absence of F-.
Nav1.5 construct Activation Inactivation
 Vh (mV) k (mV) Time to peak (ms) Vh (mV) k (mV) τf (ms) τs (ms)
WT -33.8±1.4 5.2±0.9 0.4±0.06 -72.0±4.3 6.9±0.4 0.9±0.1 9.1±1.6
p.D1816VfsX7 -12.6±1.8** 6.2±0.6 0.1±0.02** -55.3±2.3** 6.4±0.6 0.9±0.1 10.4±1.6
Vh and k, midpoint and slope of the activation and inactivation curves. τf and τs, fast and slow time constants of inactivation. Values are the mean±SEM of 10 experiments in
each group. ** P<0.01 vs WT.
doi: 10.1371/journal.pone.0081493.t004
Figure 3.  WT and p.D1816VfsX7 Nav1.5 current densities.  A. Current traces obtained by applying the protocol shown at the top
in cells transfected with WT, p.D1816VfsX7, and p.D1816VfsX7+WT. B. Current-density voltage relationships for WT,
p.D1816VfsX7, and p.D1816VfsX7+WT channels. C. Peak current density generated by each construct tested. Each point/bar
represents mean±SEM of >10 experiments. In B and C, *P<0.01 vs WT, and # P<0.01 vs p.D1816VfsX7.
doi: 10.1371/journal.pone.0081493.g003
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 and Table 3). We next analyzed the development of slow
inactivation by applying a pre-pulse to -20 mV of progressively
increasing duration followed by a test pulse also to -20 mV.
p.D1816VfsX7 mutation significantly increased the fraction of
channels that developed slow inactivation with prolonged
depolarizations (Figure 6B). Co-expression of p.D1816VfsX7
with WT channels partially reversed this alteration.
Effects of p.D1816VfsX7 mutation on channel
trafficking
In the next group of experiments, the effects of
p.D1816VfsX7 mutation on Nav1.5 trafficking using channels
conjugated with GFP were analyzed by using confocal
microscopy. Additionally, we performed a group of experiments
where we compared the currents generated by Nav1.5 WT
channels conjugated or not with GFP. As is shown in Table 5,
under our experimental conditions, current density, time-
dependent kinetics and voltage dependence of activation and
inactivation were not significantly different, confirming that the
presence of GFP does not interfere with the
electrophysiological properties of the channel. On the other
hand, the confocal microscopy results obtained demonstrated
that WT channels were distributed uniformly throughout the cell
including the cell membrane as demonstrated by the
colocalization of the GFP signal with that of the membrane
marker wheat germ agglutinin Alexa Fluor 647 (Figure 7A
upper panel). On the contrary, cells expressing p.D1816VfsX7
channels did not clearly exhibit fluorescence in the membrane
as the GFP signal was mainly localized in the cytoplasm and,
thus, colocalization was significantly decreased compared with
WT channels (Figure 7A middle panel and 7B). Membrane
fluorescence significantly increased when p.D1816VfsX7
channels were coexpressed with WT channels (Figure 7A and
B).
Previous data have demonstrated that trafficking of Nav1.5
mutant channels can be restored by decreasing incubation
temperature during cell culture or by incubation with
compounds or drugs (Class I antiarrhythmic drugs) that
improve channel trafficking [23]. Reducing the incubation
temperature during cell culture to 25°C or incubation of the
p.D1816VfsX7 transfected cells with 5 mM 4-phenylbutirate or
300 μM mexiletine for 48 h did not modify current density
compared to that recorded under control conditions (Figure
7C).
Figure 4.  Activation and inactivation voltage-dependence of WT and p.D1816VfsX7 Nav1.5 channels.  (A and B) Normalized
steady-state activation (A) and inactivation curves (B) of WT, p.D1816VfsX7, and p.D1816VfsX7+WT constructs. Solid lines
represent the Boltzmann fit to data point. Each point represents the mean±SEM of >10 experiments.
doi: 10.1371/journal.pone.0081493.g004
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Discussion
In the present study, we describe the functional
consequences of a frameshift mutation (p.D1816VfsX7) found
in a patient with repeated episodes of ventricular fibrillation who
lacks typical ECG features of BrS or long QT syndrome both
under basal conditions and after flecainide and epinephrine
challenges. There are previous reports demonstrating that loss-
of-function SCN5A mutations could result in syncope,
ventricular fibrillation, and sudden cardiac death in patients with
normal structural hearts who do not exhibit any
electrocardiographic manifestations of inherited
arrhythmogenic syndromes [6,7]. However, it is important to
note that the proband presented sinus bradycardia on basal
status and under flecainide, which could be attributed to the
p.D1816VfsX7 mutation. This hypothesis could seem
counterintuitive since pacemaker activity in sinus nodal cells is
mainly regulated by Ca2+ and K+ channels. However,
bradyarrhythmic complications have been associated with
other Nav1.5 loss-of-function mutations [24,25]. Indeed, it has
been described that Nav1.5 channels are distributed in the
periphery of the sinus node [26], and thus, it is possible that a
functional defect of Nav1.5 channel activity would lead to
reduced impulse propagation from the sinoatrial node to the
surrounding atrial muscle and, thus, to a decrease in heart
rhythm [24,25].
Genetic screening of several family members revealed that
seven of them also carry the mutation. Among them other
cardiac electrical abnormalities were detected. As mentioned,
the proband and one of her sisters exhibit paroxysmal and
permanent AF, respectively. A son and a sister of the proband
displayed type 1 BrS pattern after flecainide challenge.
Moreover, another relative carrying the mutation had suffered
an episode of syncope in the past. Additionally, PR and QRS
intervals were significantly prolonged in the mutation carriers.
Although the conduction delay is mild the concomitant
presence of both PR and QRS prolongation suggests a
hampered conduction in different cardiac compartments. Our
hypothesis is that impairment of intracardiac conduction
exhibited by mutant carriers and the BrS exhibited by two of
them, could be attributed to the marked INa decrease produced
by the mutation. Furthermore, Nav1.5 loss-of-function
mutations have been associated with atrial arrhythmias
including AF [4]. In fact, prevalence of AF and atrial flutter in
patients with BrS is very high (approximately 20%) [27].
Moreover, it has been suggested that some patients with drug-
induced BrS ECG may develop atrial arrhythmias prior to
developing ventricular fibrillation [27]. Therefore, we propose
Figure 5.  Effects of p.D1816VfsX7 mutation on the window and late Na+ currents.  A. Effects of p.D1816VfsX7 mutation on the
window current. The probability of being within this window for WT and p.D1816VfsX7 channels is plotted. B. Effects of the mutation
on the INaL. Bar graphs show the density of the current generated by WT, p.D1816VfsX7, and p.D1816VfsX7+WT constructs
measured at the end of 500-ms pulse to -20 mV from a holding potential of -120 mV. Each bar represents the mean±SEM of >12
experiments.
doi: 10.1371/journal.pone.0081493.g005
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that this severe loss-of-function mutation is associated with
incomplete penetrance and variable expressivity giving rise to a
complex phenotype which includes ventricular fibrillation,
bradycardia, intracardiac conduction delay, AF, and BrS. The
association of a single SCN5A mutation with a wide spectrum
of disease phenotypes has been described previously [8].
Unfortunately, the reasons underlying the marked heterogenity
in phenotype remain unknown. Gender and age may constitute
clinical determinants of disease expressivity. However, in our
family three sisters of similar age clearly differ in their
phenotype, i.e., ventricular fibrillation associated with
bradycardia and paroxysmal AF (the proband) vs. permanent
AF (II:8), and BrS (II:4). Moreover, epigenetic or genetic factors
including genetic variability due to the presence of
Figure 6.  Recovery from fast inactivation of WT and p.D1816VfsX7 Nav1.5 channels.  A. Recovery from fast inactivation of
WT, p.D1816VfsX7, and p.D1816VfsX7+WT constructs assessed by applying two 500 ms pulses from -120 to -20 mV (P1 and P2)
at increasing coupling intervals (0.1–500ms). Solid lines represent the fit of a biexponential function to the data points. B.
Development of slow inactivation of WT, p.D1816VfsX7, and p.D1816VfsX7+WT constructs assessed with the double-pulse
protocol shown at the top. Solid lines represent the fit of a monoexponential function to the data points. Each point (ratio of the peak
current amplitude generated by P2 and P1 pulses) represents the mean±SEM of >10 experiments and * P<0.05 vs WT.
doi: 10.1371/journal.pone.0081493.g006
Table 5. Comparison of voltage-dependence of activation and inactivation parameters between Nav1.5 conjugated or not
with GFP.
Nav1.5 construct Activation Inactivation
 Vh (mV) k (mV) Time to peak (ms) Vh (mV) k (mV) τf (ms) τs (ms)
WT -38.8±2.6 6.1±0.9 0.5±0.2 -81.7±6.0 6.1±0.4 0.9±0.2 6.3±0.7
WT-GFP -38.5±2.4 6.4±0.7 0.4±0.2 -79.2±5.5 7.1±0.8 1.1±0.8 6.2±2.0
Vh and k, midpoint and slope of the activation and inactivation curves. τf and τs, fast and slow time constants of inactivation. Values are the mean±SEM of 10 experiments in
each group.
doi: 10.1371/journal.pone.0081493.t005
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polymorphisms, may contribute to disease expressivity and
mixed phenotypes in Nav1.5 loss-of-function overlap
syndromes [8]. Therefore, unknown genetic or environmental
factors may probably account for the variable and incomplete
disease expressivity in this family.
p.D1816VfsX7 mutation produces a 201-residue truncation
of the C-terminal domain of the channel that markedly affected
channel expression and gating. Indeed, the most important
alteration of Na+ channel function produced by the mutation
was a dramatic reduction (≈90%) in peak current density as a
consequence of a significant decrease of channel trafficking
toward the membrane. Furthermore, impaired channel
trafficking was not restored by incubating transfected cells at
low temperature or with chemical chaperones such as
mexiletine or 4-phenylbutirate. Trafficking defects of mutant Na
+ channel proteins can be due to endoplasmic reticulum
retention, degradation of folding-deficient proteins or absence
of a motif essential for trafficking [28]. The C-terminal domain
of Nav1.5 channels, comprising residues 1773 to 2016,
contains several protein-protein interaction motifs including a
calmodulin-binding IQ motif (residue 1908), a PY motif (residue
1974) and a PDZ binding domain motif (3 last residues) (Figure
2). It has been described that interaction of calmodulin,
ubiquitin protein ligases and PDZ domain-bearing proteins with
these domains is needed for proper expression of the channel
[29,30]. Especially important is the interaction of Nav1.5 with
PDZ domain-bearing proteins such as the protein tyrosine
phosphatase (PTPH1), the membrane associated guanylate
kinase scaffolding protein (SAP97), and syntrophin-dystrophin
complex. These proteins recognize the C-terminal Ser-Ile-Val
Figure 7.  WT and p.D1816VfsX7 Nav1.5 channel trafficking.  A. Representative single fluorescent confocal images from the
center of CHO cells transfected with GFP-tagged-Nav1.5 WT, p.D1816VfsX7, and p.D1816VfsX7+WT constructs. Columns: GFP-
tagged-Nav1.5 channel staining (left), wheat germ agglutinin Alexa Fluor 647 (a fluorescent membrane dye) staining (middle), and
colocalization of both (right). B. Percentage of colocalized voxels measured in cells transfected with WT, p.D1816VfsX7, and
p.D1816VfsX7+WT. C. Comparison of peak current-density recorded in cells expressing p.D1816VfsX7 incubated or not at 25°C, or
in the presence of 5 mM 4-phenylbutirate (4-PB) or 300 μM mexiletine (mexi) with WT. Bars represent the mean±SEM of >6 cells. *
P<0.05 vs WT and # P<0.05 vs p.D1816VfsX7.
doi: 10.1371/journal.pone.0081493.g007
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(SIV) sequence of Nav1.5 and subsequently increase channel
expression in the membrane [29,30]. p.D1816VfsX7 mutant
channel lacks all these protein-protein interaction motifs, a fact
that provides a plausible mechanism to explain its trafficking
defect.
It is interesting to note that despite the severe truncation of
the C-terminus of Nav1.5, p.D1816VfsX7 channels generated
measurable but abnormal currents. The mutation induced
alterations in channel gating leading to a mixed loss- and gain-
of-function phenotype. Indeed, it produced a positive shift in the
voltage dependence of activation and an increase in the
fraction of channels entering the slow inactivated state, effects
that would reduce peak INav1.5. On the contrary, it positively
shifted the voltage dependence of fast inactivation and
accelerated activation and recovery from fast inactivation
kinetics, effects that would contribute to an increase in channel
availability. Interestingly, the mutation markedly reduced and
shifted the peak of the window current. The window current
determines a range of membrane potentials where Na+
channels can be activated but not inactivated. p.D1816VfsX7
mutation would lead to channel opening at more depolarized
potentials and, thus, to a further decrease in cell excitability.
However, the mutation did not modify INaL which correlates with
the lack of QT prolongation in any of the mutant carriers. Other
frameshift mutations leading to the truncation of the C-terminus
have been described (p.L1786EfsX2, p.F1808IfsX3,
p.E1823Hfs10, and p.R1860KfsX13 associated with BrS and
p.L1821fsX10 associated with sick sinus syndrome, cardiac
conduction disease and ventricular tachycardia) [11,31].
Among these mutations only p.L1821fsX10 was functionally
studied and its expression in HEK-293 cells demonstrated that
the mutation also generated currents, albeit dramatically
reduced [11]. Conversely, complete truncation of the C-terminal
domain leads to non detectable currents [32]. Thus, to our
knowledge, p.D1816VfsX7 produces the greater disruption of
Nav1.5 protein sequence for a disease causing mutation that
still generates measurable currents. Some of the effects of
p.L1821fsX10 on channel gating (shift of the activation curve to
more positive potentials, enhanced slow inactivation) were
similar to those produced by p.D1816VfsX7 [11]. However,
other effects of the p.L1821fsX10 mutation (shift of the
inactivation curve to negative potentials and increased INaL
density) were not shared by p.D1816VfsX7 mutation. It has
been described that the C-terminal cytoplasmic domain, is
important for setting the properties of fast inactivation [9,32].
Thus, it can be somewhat surprising that two frameshift
mutations p.D1816VfsX7 and p.L1821fsX10 that lead to similar
deletions of the C-terminus (201 and 195 residues,
respectively) can differentially affect voltage dependence of
fast inactivation or INaL. The proximal half of the C-terminus
contains six helical structures (H1-H6) (Figure 8) that are
critical for establishing interhelical contacts as well as
intramolecular interactions with domain III and IV linker that
stabilize the inactivated state [10,33,34]. Interestingly,
p.L1821fsX10 truncation removes H3 to H6 but leaves H1 and
H2 completely unaltered. However, p.D1816VfsX7 that also
truncated H2 (Figure 8), may impair some other interactions
different from those disrupted by p.L1821fsX10. Therefore, our
results confirm that C-terminal regions of Na+ channel mutants
may contribute to differences in gating properties of the
variants. Furthermore, our results confirm the important role of
the C-terminus for Nav1.5 channel expression and function and
demonstrate that the length of the truncated C-terminus
segment may have important implications for Na+ channel
function.
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Figure 8.  Crystalized structure of the proximal part of Nav1.5 C-terminus (PDB 4DCK).  H1 to H6 helical structures as well as
the location of D1816 have been highlighted. H1 (blue); H2 (pink); H3 (orange); H4 (red); H5 (light blue); H6 (yellow); D1816 (deep
purple).
doi: 10.1371/journal.pone.0081493.g008
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